Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
about
Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infectionBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery.Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Altered pharmacokinetics of ceftazidime in critically ill patients.Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosingComparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units)Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensIn vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsLung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumoniaRecommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Development of Antibiotic Resistance during Simulated Treatment of Pseudomonas aeruginosa in Chemostats.Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceContinuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendationContinuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?
P2860
Q24675002-EBF4615F-D5E4-4A95-B156-D770889A2F60Q24813204-2514DF10-A09B-454E-A5BF-3867B49D93D9Q33555775-58DC23C4-3986-4055-B2C8-65CAFE30785DQ33695230-C4D0EFD5-E307-4FE1-9BFE-1009492E22D9Q33695596-AA026435-4076-4B30-ABE6-F0AF7B2D383EQ33770046-4A552263-48C4-4DA9-BE71-62501DBC605BQ33977268-822DECBD-97FC-482B-A5E9-42EE4C9C0069Q33977939-C7EC4E24-7808-4731-B362-DD45F096AAF8Q34111057-291CF2F5-CD62-4CA0-8664-0C90BD9EB149Q34153182-77F46E27-28B3-4874-BF2F-3B3F24F5321DQ34381321-A8661B87-C2CF-4B74-B62E-A6AFB6234549Q35138316-07865A56-C070-40E0-B6E3-5F607824A365Q35169028-B74642EB-39B5-4FA4-8B04-71828E2FB15CQ35558292-434CA011-0B78-4A45-A593-75CF92277793Q35908084-4DC24058-2430-4BEA-BEA3-DCA48846EE0AQ35922447-4138812A-6100-4DD2-B24C-DCD81A454C23Q36053937-D75D7E09-1AC0-4178-AC33-5DB695B79A42Q36287127-24F6054C-9FB8-4162-B640-063F0FC8B0A9Q36329228-775D312D-B8BE-4793-80CE-95CE4A0FCC75Q37333080-4CE88217-9623-4AA3-B4BF-3D74C6A2D1EFQ37643682-EB71CD91-829C-4261-8AF7-24477DDA5D5FQ38167345-444CFD6C-97C1-4D23-961D-6FE6971CEA1FQ38896040-FF00693D-AFD4-45DA-AC45-3B67EF3C03CDQ42203839-D6319DB0-43B8-4C0A-BCAE-D83768410324Q42432137-25F2286C-5402-4A56-95B4-B705A7CF9657
P2860
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections
description
1996 nî lūn-bûn
@nan
1996 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մարտին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Continuous infusion versus int ...... ected gram-negative infections
@ast
Continuous infusion versus int ...... ected gram-negative infections
@en
type
label
Continuous infusion versus int ...... ected gram-negative infections
@ast
Continuous infusion versus int ...... ected gram-negative infections
@en
prefLabel
Continuous infusion versus int ...... ected gram-negative infections
@ast
Continuous infusion versus int ...... ected gram-negative infections
@en
P2093
P2860
P1476
Continuous infusion versus int ...... ected gram-negative infections
@en
P2093
P2860
P304
P407
P577
1996-03-01T00:00:00Z